Wei Ying Jen

Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified 2045 patients with HR-MDS, of which 427 (21%) underwent SCT.

ByKrina K. Patel, MD, MSc,Manali Kamdar, MD,Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting. Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel. Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.

In the phase 3 SERNEA-6 trial (NCT04964934), a clinically meaningful progression-free survival (PFS) improvement occurred in patients with emergent, ESR1-mutant, hormone receptor–positive, HER2-negative advanced breast cancer who switched from aromatase inhibition plus CDK4/6 inhibition to camizestrant plus CDK4/6 inhibitors, according to data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS).1 The updated median PFS was 16.6 months (95% CI, 14.7-19.4) with camizestrant (n =...